WeVote
Log In

Bill

Bill

HD 1139

An Act 340B Contract Pharmacy Protection Act

194th Legislature (2025-2026) Introduced by Brian Murray

Expands 340B drug program access by restricting manufacturers from limiting which contract pharmacies can dispense discounted medications to healthcare providers.

0
WeVote Research Nonpartisan
Bill Summary · HD 1139

Legislative bill overview

HD 1139 strengthens protections for contract pharmacies participating in the federal 340B drug pricing program, which allows certain healthcare entities to purchase medications at discounted rates. The bill establishes regulations to prevent manufacturer restrictions on which pharmacies can dispense these discounted drugs and requires transparency in contract pharmacy arrangements.

Why is this important

The 340B program is designed to stretch limited healthcare budgets for hospitals, clinics, and patient assistance programs serving uninsured and low-income populations. Manufacturers sometimes restrict which pharmacies can fill 340B prescriptions, limiting patient access and forcing healthcare providers to use more expensive alternatives, ultimately reducing resources available for patient care.

Potential points of contention

  • Manufacturer concerns: Drug manufacturers argue contract pharmacy restrictions protect them from diversion and ensure proper tracking of discounted medications; they may view this bill as limiting their contractual rights and increasing compliance costs.
  • Market competition: Retail and independent pharmacies may support the bill as it increases their access to 340B volume, while some pharmacy chains with existing manufacturer contracts could face disruption.
  • Implementation complexity: Defining which restrictions are permissible versus prohibited may create regulatory ambiguity and litigation risk for both manufacturers and covered entities.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.